With a large proportion of patients with JIA achieving clinical inactivity as a result of efficacious treatment with anti-TNFα biologics,2 it becomes increasing pertinent to address the lack of definitive withdrawal guidelines. This evidence concerns the gene TNF and juvenile idiopathic arthritis.